The DCR for this part of the study was greater for patients with BRAF-mutated melanoma (43.5%) compared with BRAF-WT melanoma (28.6%), although any direct comparisons between the groups are unreliable due to the small numbers of BRAF-WT patients. This evidence concerns the gene BRAF and melanoma.